Epigenomics AG

euro adhoc: Restructuring & Recapitalisations
Ad Hoc (§15 WpHG): Epigenomics AG Increases Share Capital

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Berlin, Germany - Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) announces that the Executive Board and Supervisory Board have resolved today to increase the share capital of the company against contribution in cash and without subscription rights. Epigenomics will place 2,671,088 new shares by way of a direct private placement with institutional investors in Europe. Epigenomics has received irrevocable commitments for the entire placement by a 100% subsidiary of BB MEDTECH AG (Schaffhausen, Switzerland) and funds managed by Abingworth LLP (London, UK)

The issue price has been set at EUR 1.94 per share. This constitutes a 5% premium over and above the volume-weighted average XETRA trading prices over the five trading days preceding the announcement of the capital increase. The capital raise will yield gross proceeds of approximately EUR 5.18 million. After registration of the capital increase the signed capital of Epigenomics AG will increase from its current EUR 26,723,636 to a total of EUR 29,394,724 thereafter.

Epigenomics intends to apply the proceeds from this transaction towards the final stages of product development and commercialization of its most advanced product, a blood-based molecular diagnostic test for the early detection of colorectal cancer. Proceeds will also be used for clinical R&D in its lung cancer and prostate cancer programs.

Ende of Ad hoc-Announcement

Epigenomics' Legal Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Disclaimer relating to US Securities Laws

The sale of the common stock will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. The shares will be sold pursuant to applicable exemptions from the registration requirements of the Securities Act. Unless registered, the shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities.

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368

Branche: Biotechnology
ISIN:      DE000A0BVT96
WKN:        A0BVT9
Index:    Prime All Share, Technologie All Share
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse München / free trade

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: